Development of orphan vaccines: an industry perspective

Area of Science:

• Vaccinology
• Infectious Diseases
• Pharmaceutical Development

Background:

• Vaccine development for rare emerging infectious diseases is hindered by significant financial disincentives and complex regulatory landscapes.
• Pharmaceutical companies often prioritize projects with larger market potential, leaving rare diseases underserved.
• Humanitarian concerns necessitate the development of niche vaccines for rare diseases lacking other preventive or curative options.

Purpose of the Study:

• To explore the challenges and incentives associated with developing vaccines for rare emerging infectious diseases.
• To identify key factors that can facilitate the creation of niche vaccines for orphan diseases.
• To highlight the importance of regulatory and economic frameworks in driving vaccine innovation for rare conditions.

Main Methods:

• Review of existing literature on vaccine development, rare diseases, and pharmaceutical economics.
• Analysis of regulatory frameworks, such as the U.S. Orphan Drug Act and European Commission proposals.
• Identification of contributing factors for successful orphan vaccine development through expert insights and market viability assessments.

Main Results:

• The development of vaccines for rare emerging infectious diseases is significantly impacted by research and development expenditures and regulatory complexities.
• Legislation like the U.S. Orphan Drug Act and similar European initiatives offer financial and practical incentives for rare disease drug development.
• Key factors for overcoming challenges include updated epidemiologic data, increased disease awareness, prioritized vaccine lists, dedicated organizations, and long-term economic viability.

Conclusions:

• Overcoming the disincentives for developing vaccines against rare emerging infectious diseases requires a multi-faceted approach.
• Financial incentives, regulatory support, and increased awareness are critical for fostering the development of niche vaccines.
• Strategic planning, expert collaboration, and demonstrating pharmacoeconomic viability are essential for the successful creation and adoption of orphan vaccines.